Join us to lean more about genetic haemochromatosis treatment and best practice.

Our participation in this GP education event has been made possible through the generous support of the Miss Butters Reekie Charitable Trust. This event was re-scheduled by RCGP from Glasgow in February 2021, on account of Covid-19 restrictions.

Visit us on stand J24 for further details on :

  • our award-winning venesection best practice guidance, endorsed by the Royal College of Nursing
  • our free hospital/clinic packs of venesection diaries, patient information, telephone helpline and leaflets
  • our 2020 “State of the nation” report on BSH clinical protocol uptake for GH
  • our free clinician training events and education programme
  • our ground-breaking report “The impact of iron overload”, launched at the Houses of Parliament

Genetic haemochromatosis is the UK’s most common genetic condition, directly affecting over 380,000[i] people. Although it is commonplace, the condition is significantly under-diagnosed in the UK. The NHS is caring for just 20,000[ii] people with genetic haemochromatosis.

Untreated, the condition can lead to iron overload, where the body is unable to process excess iron. Excess iron is extremely toxic. Genetic haemochromatosis can cause liver disease, cancer, heart disease, chronic fatigue, diabetes, severe joint pain, sexual health issues and neurological issues.

Early diagnosis saves lives. Diagnosed early, haemochromatosis is manageable and not life-limiting. Treatment is simple and cost effective.

Please note that due to Covid-19 this event has been re-scheduled by RCGP to October 2021.

[i] "Hereditary Haemochromatosis - Estimates of Excess Disease In The UK" (July 2019) - Professor David Melzer & the Exeter Haemochromatosis research group, University of Exeter

[ii] HUK Freedom of Information Study (2020) – Neil McClements (Haemochromatosis UK) & Gerri Mortimore (University of Derby)